Zobrazeno 1 - 10
of 601
pro vyhledávání: ''
Autor:
Dirk Waldschmidt, J-B. Bachet, Lawrence Fong, J. Tabernero, Michele Reni, H-M. Chang, Sara Lonardi, G. Cole, Margaret A. Tempero, Andrew Eugene Hendifar, D-Y. Oh, L.C. Tsao, Teresa Macarulla, Danelle F. James, E. Van Cutsem, Juan Maurel, Lisa M. Coussens, Naureen Starling, Rocio Garcia-Carbonero
Publikováno v:
Scientia
Ibrutinib; Metastatic pancreatic adenocarcinoma; Phase III Ibrutinib; Adenocarcinoma de páncreas metastásico; Fase III Ibrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III First-line treatment of metastatic pancreatic ductal adenocarcinoma
Autor:
W.S. Kim, Jin Soo Kim, T. Kim, Ho-Young Yhim, D.-H. Yang, H.-J. Shin, G.S. Park, Jinny Park, S.J. Kim, Joon Ho Moon, Youngil Koh
Publikováno v:
Annals of Oncology. 32:552-559
Background Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). Patients and methods This phase I/II st
Autor:
Joohyuk Sohn, S.-B. Kim, Konstantinos Tryfonidis, A. Wang, Peter Schmid, Eva Muñoz-Couselo, Lina Yin, Roberto Salgado, Rebecca Dent, Sherene Loi, S-A. Im, Vassiliki Karantza, J. Cortes, Sherko Kuemmel, Theodoros Foukakis, Younghee Park
Publikováno v:
Annals of Oncology. 31:569-581
Background The phase Ib KEYNOTE-173 study was conducted to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy plus pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC). Patients an
Autor:
J.H. Hong, Y.S. Park, Myung Ah Lee, Sung Heon Kim, J.W. Lee, So Young Yoon, Seungtae Kim, Jung-Hun Kang, J. O. Park, Joung-Soon Jang, Byeong Seok Sohn, S.Y. Oh, Hyungwoo Lee, M. Kim, H. Y. Lim, Hye Jin Choi
Publikováno v:
Annals of Oncology. 30:788-795
Background Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase II trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX) has been the reference arm in recent phase II and
Autor:
Y-K. Kang, L.-T. Chen, Hiroki Hara, Yoshito Komatsu, Masahiro Tsuda, Ken Kato, Hyun Cheol Chung, Mizutomo Azuma, Narikazu Boku, H. Cho, Kensei Yamaguchi, Soichi Fumita, Won Ki Kang, Keun Wook Lee, Min-Hee Ryu, Keiko Minashi
Publikováno v:
Annals of Oncology
Background Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy of first-line therapy,
Publikováno v:
Annals of Oncology
Background: Due to COVID-19, the NCCN Myeloid Growth Factor Panel expanded prophylactic G-CSF use to chemotherapy with Intermediate Risk (10%-20% risk) of Febrile Neutropenia (FN), and to Low Risk FN patients (pts) who previously developed FN Preserv
Autor:
Elizabeth Blackwood, Antoine Hollebecque, Kelly DuPree, Xuyang Lu, Sami Mahrus, Sophie Postel-Vinay, Jennifer L. Schutzman, Elaine Murray, Erika Hamilton, Sara M. Tolaney, A. Moein, Michael Tagen, J. R. Infante, Antoine Italiano, J. Epler, Kathleen N. Moore, Maud Toulmonde, Jean-Charles Soria, Jennifer O. Lauchle, Geoffrey I. Shapiro, Patricia LoRusso, Franklin Peale, Sophie Cousin
Publikováno v:
Annals of Oncology. 29:1304-1311
Background Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in
Autor:
Kensei Tobinai, Jenna Fan, Anna Vanazzi, David Belada, Anne-Laure Louveau, Michinori Ogura, T. E. Witzig, Franco Cavalli, Jean-François Larouche, Kamal Bouabdallah, C. D. Bermudez Silva, Cassandra Wu, Jiří Mayer, Luis Fayad, Jun Zhu, Masayuki Hino, Muhit Ozcan, Tadashi Ikeda, Won Seog Kim, Yuankai Shi, John Kuruvilla, Luigi Rigacci, Luciano J. Costa, Maurizio Voi, Joseph Kattan
Publikováno v:
Annals of Oncology. 29:707-714
Background Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) ≥3 are at higher risk for relapse after a complete response (CR) to first-line rituximab-based chemotherapy (R-chemo). Everolimus has single
Publikováno v:
Annals of Oncology. 32:S443
Background: Primary granulocyte-colony stimulating factor (GSCF) prophylaxis with dose-dense chemotherapy for early stage breast cancer is routine practice to prevent febrile neutropenia (FN). Our current practice administers 7 days of GCSF, which re
Publikováno v:
Annals of Oncology. 32:S1190